A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Exclusion Criteria

• •History of a clinically significant infection within 4 weeks prior to consent
• •Active bacterial, viral, and/or fungal infection
• •Prior allogeneic stem cell transplant
• •Prior lentiviral- or retroviral-based therapy including CAR-T cell therapy
• •Prior lymphodepleting or T-cell cytotoxic therapy within 3 months of enrollment
• •Subjects receiving attenuated vaccines within 4 weeks of consent or need for live vaccine within 12 months of starting study therapy
• •History of significant cardiovascular conditions within the past 6 months
• •Subjects with a prior history of or concurrent malignancy whose natural history or treatment has the potential to interfere with either the safety or efficacy assessment of the investigational regimen